*Saterland, Germany, 17 of May, 2024* — esqLABS GmbH, a leading expert in modeling and simulation, announce a groundbreaking collaboration with Sanofi in Advancing Organ-on-Chip Technology through their business unit MPSlabs. This partnership aims to revolutionize drug development through the creation of digital twins for cell-based in vitro assays, enhancing the prediction of human pharmacokinetics (PK) in drug discovery and development processes.

Innovative Approach to Drug Development

At the forefront of this initiative is the utilization of organ-on-chip (OoC) technology. This cutting-edge approach simulates human physiological responses in vitro, providing a more dynamic and accurate method for drug testing. By integrating digital twin technology, this project aims to bridge the gap between in vitro studies and human clinical outcomes, drastically improving the efficiency and reliability of drug development.

A Step Forward in Predictive Accuracy

The core objective of this venture is to significantly enhance the predictability of drug effects in humans. The use of 2D cultures of primary hepatocytes and various liver-chip technologies will provide comprehensive data to achieve this goal. Through the development of digital twins and PBPK models, esqLABS and Sanofi aim to establish a new benchmark in the precision of preclinical drug assessments.

Commitment to Advanced Ethical Drug Development

This collaboration is not just a testament to the commitment of MPSlabs and Sanofi to advancing drug development technology but also reflects their dedication to ethical research practices. By reducing the reliance on animal testing and improving the accuracy of drug safety and efficacy assessments, this project aligns with the growing global demand for more humane and effective drug development methods.

About MPSlabs

Led by Dr. Christian Maass, MPSlabs is a dedicated research and business unit situated under the umbrella of ESQlabs, led by CEO Dr. Stephan Schaller. MPSlabs spearheads the development of digital twin platforms for organ-on-chip and micro-physiological systems, bringing invaluable expertise to projects that require advanced simulation and modeling capabilities.

About ESQlabs

ESQlabs specializes in modeling and simulation, focusing on pharmacokinetics, pharmacodynamics, and physiologically based pharmacokinetic (PBPK) modeling. The company is a significant contributor to and user of the open-source OSP Suite, enhancing its development and community engagement. ESQlabs offers a range of services that include model building, refinement, data integration, and consulting in life sciences and pharmacology. With a team of more than 30 skilled scientists, the company’s expertise spans modeling, statistics, pharmacology, and software development. The OSP Suite, central to ESQlabs’ operations, is continually expanding in its applications and user base, especially in creating digital representations of human biology.

Forward-Looking Statements

This release contains forward-looking statements based on current assumptions and forecasts. While ESQlabs strives for accuracy, future events may differ materially from those set forth in these statements due to various factors.


Contact Information

Christian Maass, PhD

BU Lead MPSlabs